Interleukin-4 modulates type I interferon to augment antitumor immunity
Science Advances · 16.05.2025 · 11 (20)
DOI: 10.1126/sciadv.adt3618 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 16.05.2025. Verfasst von Hannah V Newnes und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, The University of Western Australia, Perth, Australia. Hauptthemen laut MEDLINE: Interferon Type I, Interleukin-4, Melanoma, Experimental. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Despite advances in immunotherapy, metastatic melanoma remains a considerable therapeutic challenge due to the complexity of the tumor microenvironment. Intratumoral type I interferon (IFN-I) has long been associated with improved clinical outcomes. However, several IFN-I subtypes can also paradoxically promote tumor growth in some contexts. We investigated this further by engineering murine B16 melanoma cells to overexpress various IFN-I subtypes, where a spectrum of outcomes was observed. Characterization of these tumors by RNA sequencing revealed a tumor immune phenotype, where potent IFN-I signaling concomitant with diminished type 2 inflammation failed to confer durable tumor control. T cell–mediated rejection of these tumors was restored by introducing interleukin-4 (IL-4) into the tumor microenvironment, either through ectopic expression or in a preclinical adoptive T cell therapy model. Collectively, our findings highlight the IFN-I/IL-4 axis in promoting antitumor immunity, which could be harnessed to target and stratify solid tumors that are nonresponsive to frontline therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, The University of Western Australia, Perth, Australia.
- The Kids Research Institute Australia, The University of Western Australia, Perth, Australia.
- Department of Dermatology, Otto-von-Guericke University, Magdeburg, Germany.
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
- Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Perth, Australia.
ORCID-Profile: Hannah V Newnes, Anthony C Buzzai, Emma de Jong, Katherine M Audsley, Samantha A Barnes, Shamini Srinivasan, Michael Serralha, Vanessa S Fear, Phil K Darcy, Paul A Beavis, Anthony Bosco, Jason Waithman
Zitieren
APA
Newnes, H. V., Armitage, J. D., Buzzai, A. C., de Jong, E., Audsley, K. M., Barnes, S. A., Srinivasan, S., Serralha, M., Fear, V. S., Guo, B. B., Jones, M. E., Forrest, A. R. R., Foley, B., Darcy, P. K., Beavis, P. A., Bosco, A., & Waithman, J. (2025). Interleukin-4 modulates type I interferon to augment antitumor immunity. Science Advances, 11(20). https://doi.org/10.1126/sciadv.adt3618
Vancouver
Newnes HV, Armitage JD, Buzzai AC, de Jong E, Audsley KM, Barnes SA, et al. Interleukin-4 modulates type I interferon to augment antitumor immunity. Science Advances. 2025;11(20). doi:10.1126/sciadv.adt3618
BibTeX
@article{Newnes2025,
author = {Newnes, Hannah V and Armitage, Jesse D and Buzzai, Anthony C and de Jong, Emma and Audsley, Katherine M and Barnes, Samantha A and Srinivasan, Shamini and Serralha, Michael and Fear, Vanessa S and Guo, Belinda B and Jones, Matt E and Forrest, Alistair R R and Foley, Bree and Darcy, Phil K and Beavis, Paul A and Bosco, Anthony and Waithman, Jason},
title = {Interleukin-4 modulates type I interferon to augment antitumor immunity},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {20},
doi = {10.1126/sciadv.adt3618}
}
EUVIMED